Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of The Global Health Innovative Technology.

    Client Virtual Booth

    THE GLOBAL HEALTH INNOVATIVE TECHNOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    The Global Health Innovative Technology
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    Ark Hills Sengokuyama Mori Tower 25F, 1-9-10 Roppongi, Minato-ku, Tokyo, 106-0032, JP
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ghitfund.org/en
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, ...

    Details:

    The net proceeds will be used for the lead optimization and candidate selection of a novel long-acting injectable which targets malarial electron transport chain for malaria chemoprevention and prophylaxis.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Undisclosed

    Recipient: Shionogi

    Deal Size: $2.2 million Upfront Cash: Undisclosed

    Deal Type: Funding May 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, ...

    Details:

    The net proceeds will be used to evaluate the safety, pharmacokinetic and efficacy profiles of next-generation cPheRS-inhibitor antimalarials, with potentially lower cost of treatment and improved safety profiles.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Undisclosed

    Recipient: Eisai

    Deal Size: $0.7 million Upfront Cash: Undisclosed

    Deal Type: Funding May 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, ...

    Details:

    The net proceeds will be used for the lead optimization of a novel and very promising T. cruzi active series being developed for the treatment of Chagas disease.


    Lead Product(s): Undisclosed

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Undisclosed

    Recipient: Mitsubishi Tanabe Pharma

    Deal Size: $1.9 million Upfront Cash: Undisclosed

    Deal Type: Funding May 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, ...

    Details:

    The net proceeds will be used for the preclinical development of the macrofilaricide corallopyronin A (CorA) for the treatment of onchocerciasis and lymphatic filariasis.


    Lead Product(s): Corallopyronin A

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Eisai

    Deal Size: $5.9 million Upfront Cash: Undisclosed

    Deal Type: Funding May 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search